| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/14/2009 | US20090123422 Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-y |
| 05/14/2009 | US20090123420 Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase |
| 05/14/2009 | US20090123419 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 05/14/2009 | US20090123418 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-urea to treat proliferative disease |
| 05/14/2009 | US20090123416 Methods for the treatment of bladder cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
| 05/14/2009 | US20090123411 Molecular Fingerprints With Enhanced Identifying Capability, Method for Preparing Same and Use Thereof |
| 05/14/2009 | US20090123410 Keratotic plug removing composition |
| 05/14/2009 | US20090123406 Organic therapeutic and cosmetic preparation |
| 05/14/2009 | US20090123400 Compositions and methods for reducing photosensitivity associated with photodynamic therapy |
| 05/14/2009 | US20090123399 Packaged liquid edible composition comprising carotenoids |
| 05/14/2009 | US20090123390 Compositions for the treatment of gastrointestinal inflammation |
| 05/14/2009 | US20090123389 Methods for modulating Th17 cell development in the treatment and prevention of cellulite |
| 05/14/2009 | US20090123388 Prodrugs of Short-Chain Fatty Acids and Treatment Methods |
| 05/14/2009 | US20090123387 Buccal, polar and non-polar spray or capsule containing cardiovascular or reneal drugs |
| 05/14/2009 | US20090123386 Abuse Resistant Capsules |
| 05/14/2009 | US20090123379 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor |
| 05/14/2009 | US20090123375 CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration |
| 05/14/2009 | US20090123366 Targeted Therapy |
| 05/14/2009 | DE60226044T2 Kristalline formen von fluvastatin-natrium Crystalline form of fluvastatin sodium |
| 05/14/2009 | DE212007000063U1 Feste Arzneiform von Olmesartan Medoxomil und Amlodipin Solid dosage form of olmesartan medoxomil and amlodipine |
| 05/14/2009 | DE102007054794A1 Wässrige Eisen-Dextran-Zubereitung mit ein oder mehreren Verbindungen der para-Hydroxy-Benzoesäureester und/oder deren Salzen Aqueous iron-dextran preparation containing one or more compounds of the para-hydroxy-benzoic acid esters and / or salts thereof |
| 05/14/2009 | CA2714808A1 Selective estrogen receptor modulator compositions and methods for treatment of disease |
| 05/14/2009 | CA2713394A1 Anti-inflammatory quinic acid derivatives for oral administration |
| 05/14/2009 | CA2705316A1 Modulation of factor 7 expression |
| 05/14/2009 | CA2705303A1 Modulation of protein trafficking |
| 05/14/2009 | CA2705246A1 Peptide deformylase inhibitors |
| 05/14/2009 | CA2705159A1 Methods for administering corticosteroid formulations |
| 05/14/2009 | CA2705153A1 Intranasal compositions |
| 05/14/2009 | CA2705150A1 Substituted cyclopentanes having prostaglandin activity |
| 05/14/2009 | CA2705138A1 Solubilized thiazolopyridines |
| 05/14/2009 | CA2705113A1 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors |
| 05/14/2009 | CA2705097A1 Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists |
| 05/14/2009 | CA2705092A1 Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| 05/14/2009 | CA2705063A1 Fast release solid formulation, preparation and use thereof |
| 05/14/2009 | CA2705050A1 Compositions for the treatment and prevention of eyelid swelling |
| 05/14/2009 | CA2705049A1 Therapy option for recoloration of hair via bisphosphonates by physiological repigmentation with age-related and/or premature "grayed" patients |
| 05/14/2009 | CA2705014A1 Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates |
| 05/14/2009 | CA2704981A1 Aldh-2 inhibitors in the treatment of psychiatric disorders |
| 05/14/2009 | CA2704977A1 Prevention and treatment of secondary infections following viral infection |
| 05/14/2009 | CA2704921A1 Compositions and methods for treating parkinson's disease and related disorders |
| 05/14/2009 | CA2704859A1 Topical treatment with dapsone in g6pd-deficient patients |
| 05/14/2009 | CA2704853A1 Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties |
| 05/14/2009 | CA2704803A1 7-azaindole derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| 05/14/2009 | CA2704684A1 Compounds which modulate the cb2 receptor |
| 05/14/2009 | CA2704663A1 Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction |
| 05/14/2009 | CA2704649A1 Tetracyclic dipyrano-coumarin compounds with anti-hiv and anti-mycobacterium tuberculosis activities |
| 05/14/2009 | CA2704648A1 Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| 05/14/2009 | CA2704646A1 Sustained-release tablets with hydromorphone |
| 05/14/2009 | CA2704645A1 Non-nucleoside reverse transcriptase inhibitors |
| 05/14/2009 | CA2704640A1 Extract of fraxinus excelsior seeds and therapeutic applications therefor |
| 05/14/2009 | CA2704633A1 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| 05/14/2009 | CA2704556A1 West nile virus vaccine, and method for production thereof |
| 05/14/2009 | CA2704549A1 Use of oligonucleotides with modified bases as antiviral agents |
| 05/14/2009 | CA2704523A1 Use of a gestagen in combination with an estrogen and one or more pharmaceutically tolerable excipients/carriers for lactose-free oral contraceptive |
| 05/14/2009 | CA2704474A1 Wet granulation using a water sequestering agent |
| 05/14/2009 | CA2704473A1 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| 05/14/2009 | CA2704380A1 Avenanthramide-containing compositions |
| 05/14/2009 | CA2704222A1 Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| 05/14/2009 | CA2704000A1 Combination of anti-angiogenic substance and anti-tumor platinum complex |
| 05/14/2009 | CA2703996A1 Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| 05/14/2009 | CA2703994A1 Use of vitamin d receptor agonists and precursors to treat fibrosis |
| 05/14/2009 | CA2703987A1 Cyclobutyl carboxylic acid derivatives |
| 05/14/2009 | CA2703872A1 Lidocaine tape preparation |
| 05/14/2009 | CA2703792A1 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
| 05/14/2009 | CA2703781A1 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465 |
| 05/14/2009 | CA2703621A1 Use of tam receptor inhibitors as antimicrobials |
| 05/14/2009 | CA2703598A1 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
| 05/14/2009 | CA2703511A1 Crystalline hydrate of betamimetika and use as medicament thereof |
| 05/14/2009 | CA2703497A1 A method of hormone suppression in humans |
| 05/14/2009 | CA2703260A1 Method and compounds for modulating insulin production |
| 05/14/2009 | CA2703000A1 Water-immiscible materials as vehicles for drug delivery |
| 05/14/2009 | CA2702995A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | CA2702990A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | CA2702985A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | CA2702630A1 Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| 05/14/2009 | CA2696807A1 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| 05/13/2009 | EP2058393A1 Compositions and methods for preventing and treating immune-mediated inflammatory disorders |
| 05/13/2009 | EP2058332A1 Use of CD25 binding molecules in steroid-resistant patients |
| 05/13/2009 | EP2058320A1 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 05/13/2009 | EP2058317A1 Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
| 05/13/2009 | EP2058314A1 Pyrrolotriazine compounds as kinase inhibitors |
| 05/13/2009 | EP2058313A2 Process for synthesis and purification of anhydrous crystalline S-zopiclone |
| 05/13/2009 | EP2058312A1 SMAC mimetic compounds as apoptosis inducers |
| 05/13/2009 | EP2058311A2 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine |
| 05/13/2009 | EP2058310A1 Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor comprising the derivative |
| 05/13/2009 | EP2058309A1 Fused heterocyclic compound |
| 05/13/2009 | EP2058308A1 Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. |
| 05/13/2009 | EP2058307A1 Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases |
| 05/13/2009 | EP2058306A1 Heteroaryl-substituted 2-pyridinyl-methylamine derivatives |
| 05/13/2009 | EP2058305A1 Urea derivative |
| 05/13/2009 | EP2058304A1 P2x4 receptor antagonist |
| 05/13/2009 | EP2058302A1 Method for producing phenoxypyridine derivative |
| 05/13/2009 | EP2058301A1 Pyrrolidine analogue for preventing neurogenic pain and method for production thereof |
| 05/13/2009 | EP2058298A2 Process of hydrocyanation of unsaturated carboxylic acid derivatives |
| 05/13/2009 | EP2058296A1 New crystalline form VI of agomelatine, method of preparation and pharmaceutical compositions thereof |
| 05/13/2009 | EP2058293A1 Lipoxin compounds and their use in treating cell proliferative disorders |
| 05/13/2009 | EP2058010A1 Pharmaceutical composition |
| 05/13/2009 | EP2058008A1 Anti-obesity agent and use thereof |
| 05/13/2009 | EP2057999A2 Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| 05/13/2009 | EP2057997A1 Preventive and/or therapeutic agent for peripheral neuropathy |